WORCESTER, Mass., Dec. 13, 2010 /PRNewswire/ — Generex
Biotechnology Corporation (www.generex.com) (OTC Bulletin
Board:
GNBT) announced today that the peer-reviewed scientific journal
Diabetes, Obesity and Metabolism has published new positive
data in respect of Generex Oral-lyn™, the Company’s
proprietary buccal insulin spray product.
The paper, entitled Buccal spray insulin in subjects with
impaired glucose tolerance: the prevoral study, appears in
Volume 13, Issue 1 (January 2011) of the journal and is co-authored
by a team from the Department of Endocrinology and Diabetes,
University Campus Bio-Medico, Rome, Italy led by Professor Paolo
Pozzilli and including: A. Palermo, N. Napoli, S. Manfrini, A.
Lauria, and R. Strollo.
People affected by impaired glucose tolerance (IGT) represent
more than 20% of the world’s population and the prevalence of the
condition is growing. Approximately one-third of people with
IGT develop clinical type 2 diabetes mellitus within three to five
years of an IGT diagnosis. More significantly, an increased
risk for cardiovascular disease has been observed in IGT patients,
even where type 2 diabetes does not develop. Although diet
and exercise (the treatment for IGT suggested by current American
Diabetes Association guidelines) delay the onset of type 2
diabetes, long-term prospects are poor.
Because a reduced first phase insulin response is a key factor
in diagnosing IGT, the use of insulin therapy to reduce
post-prandial glucose levels could be a targeted treatment for IGT.
However, insulin therapy via subcutaneous injection is often
rejected by patients and its use is generally limited to patients
with type 2 diabetes where oral hypoglycaemic options have
failed.
In Professor Pozzilli’s proof-of-concept study, 31 subjects
diagnosed with IGT,
‘/>”/>
